CORDIS
EU research results

CORDIS

English EN

New molecular targets and proof-of-concept therapies for Autism Spectrum Disorders

Project information

Grant agreement ID: 851231

Status

Ongoing project

  • Start date

    1 March 2020

  • End date

    28 February 2025

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 1 499 025

  • EU contribution

    € 1 499 025

Hosted by:

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

Project description

English EN

Shrinking the autism research gap

Diagnosed before age 3 based on behavioural cues, autism is a major multifactorial neurodevelopmental disorder, affecting 1 in 100 child births worldwide. There is no cure and what is more, there is no one size fits all approach to autism management. The EU-funded THERAUTISM project will aim to shrink the autism research gap to expose the common molecular and cellular dysfunctions underlying autism-related behaviours. It will also investigate the possibility for a safe gene therapy vector – after it takes into account the properties of a new protein function to restore this new target and rescue social deficits in different preclinical models of autism. The aim is to validate new molecular therapeutic targets.

Host institution

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

Address

Rue Michel Ange 3
75794 Paris

France

Activity type

Research Organisations

EU Contribution

€ 1 499 025

Beneficiaries (1)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 1 499 025

Project information

Grant agreement ID: 851231

Status

Ongoing project

  • Start date

    1 March 2020

  • End date

    28 February 2025

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 1 499 025

  • EU contribution

    € 1 499 025

Hosted by:

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France